
CLAIMS

1. A compound represented by the following Formula [I] or a pharmacologically acceptable salt thereof:




[I]

wherein,

a ring A represents an aryl group which may be substituted, a heteroaryl group which may be substituted, or an aliphatic heterocyclyl group which may be substituted, and

R^1 and R^2 represent, indipendently, an alkyl group which may be substituted, a cycloalkyl group which may be substituted, an alkenyl group which may be substituted, a cycloalkenyl group which may be substituted, an alkynyl group which may be substituted, an aryl group which may be substituted, a heteroaryl group which may be substituted, an aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring, an amino group which may be substituted, an alkoxy group which may be substituted or an alkylthio group which may be substituted, or a group in which R^1 and R^2 together form a ring.

2. The compound or the pharmacologically acceptable salt thereof according to claim 1, wherein the compound of Formula [I] is a compound represented by the following Formula [II]:



[II]

wherein,

a ring A represents an aryl group which may be substituted, a heteroaryl group which may be substituted, or an aliphatic heterocyclyl group which may be substituted,

a ring B represents an aliphatic heterocyclyl group which may be substituted

and may have a double bond in a part of a ring, and

a ring C represents an aryl group which may be substituted and may be partially hydrogenated, a heteroaryl group which may be substituted and may be partially hydrogenated, a cycloalkyl group which may be substituted, or an aliphatic heterocyclyl group which may be substituted.

3. The compound or the pharmacologically acceptable salt thereof according to claim 2, wherein in the group represented by Formula [II],

each of substituents of the aryl group which may be substituted, the heteroaryl group which may be substituted, and the aliphatic heterocyclyl group which may be substituted represented by the ring A is one to three groups independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, an alkoxyalkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, an alkoxycarbonyl group, an amino group which may be substituted with one to two alkyl groups, an alkylthio group, a sulfonyl group which may be substituted with an alkyl group, an aminocarbonyl group which may be substituted with one to two alkyl groups, a nitro group, and an aryl group,

an aryl moiety of the aryl group which may be substituted represented by the ring A is a 6- to 10-membered monocyclic or bicyclic aryl,

a heteroaryl moiety of the heteroaryl group which may be substituted represented by the ring A is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted represented by the ring A is a 5- to 10-membered monocyclic or bicyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

each of substituents of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of the ring represented by the ring B; the aryl group which may be substituted and may be partially hydrogenated represented by the ring C; the heteroaryl group which may be substituted and may be partially hydrogenated represented by the ring C; the cycloalkyl group which may be substituted represented by the ring C; and the aliphatic heterocyclyl group which may be substituted represented by the ring C is one to eight groups independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; a cyano group; an alkyl group; a haloalkyl group; an alkoxyalkyl group; an alkoxy group; a

cycloalkoxy group which may be substituted with a cyano group; a haloalkoxy group; an alkylene group which may be substituted with one to two groups independently selected from the group consisting of a halogen atom; an amino group which may be substituted with one to two groups independently selected from the group consisting of an alkyl group which may be substituted with a cycloalkyl group or an aryl group, an aryl group which may be substituted with a halogen atom, and a cycloalkyl group; an alkylthio group; an aryl group; a cycloalkyl group which may be substituted with one to two groups independently selected from the group consisting of a halogen atom and a haloalkyl group; an aliphatic heterocyclyl group which may be substituted with one to four groups independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkylene group, and an alkoxy group; an alkanoyl group which may be substituted with one to two groups independently selected from the group consisting of a cycloalkyl group, an aryl group, and an alkoxy group; an aryloxy group; an aliphatic heterocyclyl oxy group; and an alkoxycarbonyl group which may be substituted with an aryl group,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is a 5- to 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

an aryl moiety of the aryl group which may be substituted and may be partially hydrogenated represented by the ring C is a 6- to 10-membered monocyclic or bicyclic aryl,

a heteroaryl moiety of the heteroaryl group which may be substituted and may be partially hydrogenated represented by the ring C is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted represented by the ring C is a 4- to 9-membered monocyclic or bicyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

in each of the substituents of the groups represented by the ring B or the ring C, the aryl group in the selected group is a 6- to 10-membered monocyclic or bicyclic aryl, and

in each of the substituents of the groups represented by the ring B or the ring C, the aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted in the selected group is a 4- to 9-membered monocyclic or bicyclic aliphatic

heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

4. The compound or the pharmacologically acceptable salt thereof according to claim 2 or 3, wherein in the group represented by Formula [II],

the ring A is an aryl group which may be substituted or a heteroaryl group which may be substituted,

an aryl moiety of the aryl group which may be substituted represented by the ring A is a 6- to 10-membered monocyclic or bicyclic aryl,

a heteroaryl moiety of the heteroaryl group which may be substituted represented by the ring A is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B, may be substituted is a 5- to 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

the ring C is an aryl group which may be substituted and may be partially hydrogenated, a heteroaryl group which may be substituted and may be partially hydrogenated, a cycloalkyl group which may be substituted, or an aliphatic heterocyclyl group which may be substituted,

an aryl moiety of the aryl group which may be substituted and may be partially hydrogenated represented by the ring C is a 6- to 10-membered monocyclic or bicyclic aryl,

a heteroaryl moiety of the heteroaryl group which may be substituted and may be partially hydrogenated represented by the ring C is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, and

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted represented by the ring C is a 4- to 9-membered monocyclic or bicyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

5. The compound or the pharmacologically acceptable salt thereof according to any one of claims 2 to 4, wherein in the group represented by Formula [II],

the ring A is a phenyl group which may be substituted or a monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the monocyclic heteroaryl group which may be substituted represented by the ring A is one to two groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, and a nitro group,

a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted represented by the ring A is a 5- or 6-membered monocyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

a substituent of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring is represented by the ring B is one to four groups independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; an alkyl group; a haloalkyl group; an alkoxyalkyl group; an alkoxy group; an alkylene group which may be substituted with one to two groups independently selected from a halogen atom; a cycloalkyl group; an alkanoyl group which may be substituted with one to two groups independently selected from the group consisting of a cycloalkyl group, an aryl group, and an alkoxy group; and an alkoxycarbonyl group which may be substituted with an aryl group,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is a 5- to 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

in the substituents of the groups represented by the ring B, the aryl group in the selected group is phenyl,

the ring C is a phenyl group which may be substituted, a monocyclic heteroaryl group which may be substituted and may be partially hydrogenated, a monocyclic cycloalkyl group which may be substituted, or a monocyclic aliphatic heterocyclyl group which may be substituted,

each of substituents of the phenyl group which may be substituted, the monocyclic heteroaryl group which may be substituted and may be partially hydrogenated, the monocyclic cycloalkyl group which may be substituted, or the monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is one to four groups independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; a cyano group; an alkyl group; a haloalkyl group; an alkoxy group; a cycloalkoxy group which may be substituted with a

cyano group; a haloalkoxy group; an alkylene group; an amino group which may be substituted with one to two groups independently selected from the group consisting of an alkyl group which may be substituted with a cycloalkyl group or an aryl group, an aryl group which may be substituted with a halogen atom, and a cycloalkyl group; an alkylthio group; an aryl group; a cycloalkyl group which may be substituted with one to two groups independently selected from the group consisting of a halogen atom and a haloalkyl group; an aliphatic heterocyclyl group which may be substituted with one to four groups independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkylene group, and an alkoxy group; an aryloxy group; an aliphatic heterocyclyl oxy group; and an alkanoyl group,

a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted and may be partially hydrogenated represented by the ring C is a 5- or 6-membered monocyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

an aliphatic heterocyclic moiety of the monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is a 4- to 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

in each of the substituents of the groups represented by the ring C, the aryl group in the selected group is phenyl, and

in each of the substituents of the groups represented by the ring C, an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted in the selected group is a 4- to 9-membered monocyclic or bicyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

6. The compound or the pharmacologically acceptable salt thereof according to any one of claims 2 to 5, wherein in the group represented by Formula [II],

the ring A is a phenyl group which may be substituted or a monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the monocyclic heteroaryl group which may be substituted represented by the ring A is one to two groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, and a nitro group,

a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted represented by the ring A is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl,

oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, or triazinyl,

a substituent of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is one to four groups independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; an alkyl group; a haloalkyl group; an alkoxyalkyl group; an alkoxy group; an alkylene group which may be substituted with one to two groups independently selected from a halogen atom; a cycloalkyl group; an alkanoyl group which may be substituted with one to two groups independently selected from the group consisting of a cycloalkyl group, an aryl group, and an alkoxy group; and an alkoxycarbonyl group which may be substituted with an aryl group,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is azolidinyl, diazolidinyl, azinanyl, oxazinanyl, diazinanyl, thiazinanyl, azepanyl, oxazepanyl, diazepanyl, or thiazepanyl,

in the substituents of the groups represented by the ring B, the aryl group in the selected group is phenyl,

the ring C is a phenyl group which may be substituted, a monocyclic heteroaryl group which may be substituted and may be partially hydrogenated, a monocyclic cycloalkyl group which may be substituted, or a monocyclic aliphatic heterocyclyl group which may be substituted,

each of substituents of the phenyl group which may be substituted; the monocyclic heteroaryl group which may be substituted and may be partially hydrogenated; the monocyclic cycloalkyl group which may be substituted; or the monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is one to four groups independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; a cyano group; an alkyl group; a haloalkyl group; an alkoxy group; a cycloalkoxy group which may be substituted with a cyano group; a haloalkoxy group; an alkylene group; an amino group which may be substituted with one to two groups independently selected from the group consisting of an alkyl group which may be substituted with a cycloalkyl group or an aryl group, an aryl group which may be substituted with a halogen atom, and a cycloalkyl group; an alkylthio group; an aryl group; a cycloalkyl group which may be substituted with one to two groups independently selected from the group consisting of a halogen atom and a haloalkyl group; an aliphatic heterocyclyl group which may be substituted with one to four groups independently selected from the group consisting of a halogen atom, a

cyano group, an alkyl group, a haloalkyl group, an alkylene group, and an alkoxy group; an aryloxy group; an aliphatic heterocyclyl oxy group; and an alkanoyl group,

a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted and may be partially hydrogenated represented by the ring C, may be substituted is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, or triazinyl,

an aliphatic heterocyclic moiety of the monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is azetidinyl, oxetanyl, oxolanyl, azolidinyl, thiolanyl, oxazolidinyl, diazolidinyl, thiazolidinyl, oxanyl, azinanyl, dioxanyl, oxazinanyl, diazinanyl, thiazinanyl, thianyl, oxepanyl, azepanyl, thiepanyl, oxazepanyl, diazepanyl, or thiazepanyl,

in each of the substituents of the groups represented by the ring C, the aryl group in the selected group is phenyl, and

in each of the substituents of the groups represented by the ring C, an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted in the selected group is azetidinyl, oxetanyl, oxolanyl, azolidinyl, thiolanyl, oxazolidinyl, diazolidinyl, thiazolidinyl, oxanyl, azinanyl, dioxanyl, oxazinanyl, diazinanyl, thiazinanyl, thianyl, oxepanyl, azepanyl, thiepanyl, oxazepanyl, diazepanyl, thiazepanyl, or a ring in which two aliphatic heterocyclic rings are fused or bonded by a spiro atom.

7. The compound or the pharmacologically acceptable salt thereof according to any one of claims 2 to 6, wherein in the group represented by Formula [II],

the ring B is a 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring, and

the ring C is a phenyl group which may be substituted, a 6-membered monocyclic heteroaryl group which may be substituted and may be partially hydrogenated, or a 6-membered monocyclic aliphatic heterocyclyl group which may be substituted.

8. The compound or the pharmacologically acceptable salt thereof according to claim 7, wherein in the group represented by Formula [II],

the ring A is a phenyl group which may be substituted or a monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the monocyclic heteroaryl group which may be substituted represented by the ring A is one

to two groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, and a nitro group,

a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted represented by the ring A is a 5- or 6-membered monocyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

the ring B is a 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring,

a substituent of the 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is one to four groups independently selected from the group consisting of a halogen atom; an oxo group; an alkyl group; an alkoxyalkyl group; an alkylene group; a cycloalkyl group; an alkanoyl group which may be substituted with one to two groups independently selected from the group consisting of a cycloalkyl group, a phenyl group, and an alkoxy group; and an alkoxycarbonyl group which may be substituted with an aryl group,

an aliphatic heterocyclic moiety of the 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is a 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

the ring C is a phenyl group which may be substituted, a 6-membered monocyclic heteroaryl group which may be substituted and may be partially hydrogenated, or a 6-membered monocyclic aliphatic heterocyclyl group which may be substituted,

each of substituents of the phenyl group which may be substituted, the 6-membered monocyclic heteroaryl group which may be substituted and may be partially hydrogenated, or the 6-membered monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is one to two groups independently selected from the group consisting of a halogen atom; an oxo group; a cyano group; an alkyl group; a haloalkyl group; an alkoxy group; a cycloalkoxy group which may be substituted with a cyano group; a haloalkoxy group; an amino group which may be substituted with one to two groups independently selected from the group consisting of an alkyl group which may be substituted with a cycloalkyl group or an aryl group, an aryl group which may be substituted with a halogen atom, and a cycloalkyl group; a cycloalkyl group; an aliphatic heterocyclyl group which may be substituted with one to

four groups independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkylene group, and an alkoxy group; an aryloxy group; an aliphatic heterocyclyl oxy group; and an alkanoyl group,

in each of the substituents of the groups represented by the ring C, the aryl group in the selected group is phenyl,

in each of the substituents of the groups represented by the ring C, an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted in the selected group is a 5- to 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, or a ring in which two aliphatic heterocyclic rings are fused or bonded by a spiro atom,

a heteroaryl moiety of the 6-membered monocyclic heteroaryl group which may be substituted and may be partially hydrogenated represented by the ring C is a 6-membered monocyclic heteroaryl having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, and

an aliphatic heterocyclic moiety of the 6-membered monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is a 6-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

9. The compound or the pharmacologically acceptable salt thereof according to claim 7 or 8, wherein in the group represented by Formula [II],

a heteroaryl moiety of the heteroaryl group which may be substituted represented by the ring A is thienyl or pyridyl,

an aliphatic heterocyclic moiety of the 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is azepanyl, oxazepanyl, diazepanyl, or thiazepanyl,

an aryl moiety of the aryl group in the substituent of the group represented by the ring B is phenyl,

a heteroaryl moiety of the 6-membered monocyclic heteroaryl group which may be substituted and may be partially hydrogenated represented by the ring C is pyridyl, pyrazinyl, or pyrimidinyl,

an aliphatic heterocyclic moiety of the 6-membered monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is oxazinanyl,

in each of the substituents of the groups represented by the ring C, the aryl group in the selected group is phenyl, and

in each of the substituents of the groups represented by the ring C, an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted in the selected group is azolidinyl, azinanyl, oxazinanyl, diazinanyl, azepanyl, or oxazepanyl.

10. The compound or the pharmacologically acceptable salt thereof according to any one of claims 2 to 6, wherein in the group represented by Formula [II],

the ring B is a 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring, and

the ring C is a 5-membered monocyclic heteroaryl group which may be substituted or a 5-membered monocyclic aliphatic heterocyclyl group which may be substituted.

11. The compound or the pharmacologically acceptable salt thereof according to claim 10, wherein in the group represented by Formula [II],

the ring A is a phenyl group which may be substituted,

a substituent of the phenyl group which may be substituted represented by the ring A is a halogen atom,

the ring B is a 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring,

a substituent of the 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is one to four groups independently selected from the group consisting of an oxo group; an alkyl group; and an alkylene group which may be substituted with one to two groups independently selected from a halogen atom,

an aliphatic heterocyclic moiety of the 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is a 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

the ring C is a 5-membered monocyclic heteroaryl group which may be substituted or a 5-membered monocyclic aliphatic heterocyclyl group which may be substituted,

each of substituents of the 5-membered monocyclic heteroaryl group which may be substituted or the 5-membered monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is one to two groups independently selected from the group consisting of a halogen atom; an alkyl group; a haloalkyl group;

an alkylene group; a cycloalkyl group which may be substituted with one to two groups independently selected from the group consisting of a halogen atom and a haloalkyl group; and an aryl group,

in each of the substituents of the groups represented by the ring C, the aryl group in the selected group is phenyl,

a heteroaryl moiety of the 5-membered monocyclic heteroaryl group which may be substituted represented by the ring C is a 5-membered monocyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, and

an aliphatic heterocyclic moiety of the 5-membered monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is a 5-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

12. The compound or the pharmacologically acceptable salt thereof according to claim 10 or 11, wherein in the group represented by Formula [II],

an aliphatic heterocyclic moiety of the 7-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is azepanyl, oxazepanyl, or diazepanyl,

a heteroaryl moiety of the 5-membered monocyclic heteroaryl group which may be substituted represented by the ring C is imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, or triazolyl,

an aliphatic heterocyclic moiety of the 5-membered monocyclic aliphatic heterocyclyl group which may be substituted represented by the ring C is azolidinyl, and

in each of the substituents of the groups represented by the ring C, the aryl group in the selected group is phenyl.

13. The compound or the pharmacologically acceptable salt thereof according to any one of claims 2 to 6, wherein in the group represented by Formula [II],

the ring B is a 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring, and

the ring C is a phenyl group which may be substituted or a 6-membered monocyclic heteroaryl group which may be substituted.

14. The compound or the pharmacologically acceptable salt thereof according to

claim 13, wherein in the group represented by Formula [II],

the ring A is a phenyl group which may be substituted,

a substituent of the phenyl group which may be substituted represented by the ring A is a halogen atom,

the ring B is a 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring,

a substituent of the 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is one to three groups independently selected from the group consisting of an oxo group; an alkyl group; and a haloalkyl group,

an aliphatic heterocyclic moiety of the 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is a 6-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

the ring C is a phenyl group which may be substituted or a 6-membered monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the 6-membered monocyclic heteroaryl group which may be substituted represented by the ring C is a group independently selected from the group consisting of a halogen atom and a haloalkyl group, and

a heteroaryl moiety of the 6-membered monocyclic heteroaryl group which may be substituted represented by the ring C is a 6-membered monocyclic heteroaryl having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

15. The compound or the pharmacologically acceptable salt thereof according to claim 13 or 14, wherein in the group represented by Formula [II],

an aliphatic heterocyclic moiety of the 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is azinanyl, oxazinanyl, or diazinanyl, and

a heteroaryl moiety of the 6-membered monocyclic heteroaryl group which may be substituted represented by the ring C is pyridyl.

16. The compound or the pharmacologically acceptable salt thereof according to any one of claims 2 to 6, wherein in the group represented by Formula [II],

the ring B is a 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring, and

the ring C is a 5-membered monocyclic heteroaryl group which may be substituted.

17. The compound or the pharmacologically acceptable salt thereof according to claim 16, wherein in the group represented by Formula [II],

the ring A is a phenyl group which may be substituted,

a substituent of the phenyl group which may be substituted represented by the ring A is a halogen atom,

the ring B is a 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring,

a substituent of the 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is one to two groups independently selected from the group consisting of an oxo group and an alkyl group,

an aliphatic heterocyclic moiety of the 6-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is a 6-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

the ring C is a 5-membered monocyclic heteroaryl group which may be substituted,

a substituent of the 5-membered monocyclic heteroaryl group which may be substituted represented by the ring C is one to two groups independently selected from the group consisting of a halogen atom; an alkyl group; a haloalkyl group; and a cycloalkyl group which may be substituted with one to two groups independently selected from the group consisting of a halogen atom and a haloalkyl group, and

a heteroaryl moiety of the 5-membered monocyclic heteroaryl group which may be substituted represented by the ring C is a 5-membered monocyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

18. The compound or the pharmacologically acceptable salt thereof according to claim 16 or 17, wherein in the group represented by Formula [II],

an aliphatic heterocyclic moiety of the 6-membered monocyclic aliphatic

heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is diazinanyl, and

a heteroaryl moiety of the 5-membered monocyclic heteroaryl group which may be substituted represented by the ring C is pyrrolyl, imidazolyl, pyrazolyl, or triazolyl.

19. The compound or the pharmacologically acceptable salt thereof according to any one of claims 2 to 6, wherein in the group represented by Formula [I],

the ring B is a 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring, and

the ring C is a phenyl group which may be substituted or a 6-membered monocyclic heteroaryl group which may be substituted.

20. The compound or the pharmacologically acceptable salt thereof according to claim 19, wherein in the group represented by Formula [II],

the ring A is a phenyl group which may be substituted,

a substituent of the phenyl group which may be substituted represented by the ring A is one to two groups independently selected from the group consisting of a halogen atom, an alkyl group, and an alkoxy group,

the ring B is a 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring,

a substituent of the 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is one to three groups independently selected from the group consisting of a hydroxyl group; an oxo group; an alkyl group; and an alkylene group,

an aliphatic heterocyclic moiety of the 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is a 5-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

the ring C is a phenyl group which may be substituted or a 6-membered monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the 6-membered monocyclic heteroaryl group which may be substituted represented by the ring C is a group independently selected from the group consisting of a halogen atom; an alkyl group; a haloalkyl group; and an alkoxy group, and

a heteroaryl moiety of the 6-membered monocyclic heteroaryl group which may be substituted represented by the ring C is a 6-membered monocyclic heteroaryl having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

21. The compound or the pharmacologically acceptable salt thereof according to claim 19 or 20, wherein in the group represented by Formula [II],

an aliphatic heterocyclic moiety of the 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is azolidinyl or diazolidinyl, and

a heteroaryl moiety of the 6-membered monocyclic heteroaryl group which may be substituted represented by the ring C is pyridyl.

22. The compound or the pharmacologically acceptable salt thereof according to any one of claims 2 to 6, wherein in the group represented by Formula [II],

the ring B is a 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring, and

the ring C is a 5-membered monocyclic heteroaryl group which may be substituted.

23. The compound or the pharmacologically acceptable salt thereof according to claim 22, wherein in the group represented by Formula [II],

the ring A is a phenyl group which may be substituted,

a substituent of the phenyl group which may be substituted represented by the ring A is a halogen atom,

the ring B is a 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring,

a substituent of the 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is one to two groups independently selected from the group consisting of an oxo group and an alkyl group,

an aliphatic heterocyclic moiety of the 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is a 5-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

the ring C is a 5-membered monocyclic heteroaryl group which may be substituted,

a substituent of the 5-membered monocyclic heteroaryl group which may be substituted represented by the ring C is an alkyl group, and

a heteroaryl moiety of the 5-membered monocyclic heteroaryl group which may be substituted represented by the ring C is a 5-membered monocyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

24. The compound or the pharmacologically acceptable salt thereof according to claim 20 or 21, wherein in the group represented by Formula [II],

an aliphatic heterocyclic moiety of 5-membered monocyclic aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring B is azolidinyl, and

a heteroaryl moiety of the 5-membered monocyclic heteroaryl group which may be substituted represented by the ring C is thiazolyl.

25. A compound selected from the group consisting of:

(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-8-(trifluoromethyl)-2,3-dihydropyrido[3,4-f][1,4]oxazepin-5-one;

(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-7-(trifluoromethyl)-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one;

(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-8-(trifluoromethoxy)-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one;

(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-8-(trifluoromethyl)-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one;

(6R)-2-(1-fluorocyclopropyl)-5-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-7,8-dihydro-6H-thiazolo[5,4-c]azepin-4-one;

(7R)-2-[(1S*,5R*)-3-azabicyclo[3.1.0]hexan-3-yl]-6-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-7-methyl-7,8-dihydropyrimido[5,4-f]oxazepin-5-one;

(6R)-7-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-2,6-dimethyl-5,6-dihydrothiazolo[5,4-f][1,4]oxazepin-8-one;

(6R)-2-(1,1-difluoroethyl)-7-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-5,6-dihydrothiazolo[5,4-f][1,4]oxazepin-8-one;

(6R)-2-cyclopropyl-7-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-

6-methyl-5,6-dihydrothiazolo[5,4-f][1,4]oxazepin-8-one;

(6R)-2-(1-fluorocyclopropyl)-7-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-5,6-dihydrothiazolo[5,4-f][1,4]oxazepin-8-one;

(6R)-2-cyclopropyl-5-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-7,8-dihydro-6H-pyrazolo[1,5-a][1,4]diazepin-4-one;

(6R)-2-(1-fluorocyclopropyl)-5-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-7,8-dihydro-6H-pyrazolo[1,5-a][1,4]diazepin-4-one;

(6R)-5-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-2-(trifluoromethyl)-7,8-dihydro-6H-pyrazolo[1,5-a][1,4]diazepin-4-one;

(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3,8-dimethyl-2,3-dihydropyrido[3,4-f][1,4]oxazepin-5-one;

(3R)-8-cyclopropyl-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-2,3-dihydropyrido[3,4-f][1,4]oxazepin-5-one;

(3R)-8-cyclopropyl-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one;

(7R)-6-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-2,7-dimethyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one;

(7R)-2-cyclopropyl-6-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-7-methyl-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5-one;

(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-8-(trifluoromethyl)-2,3-dihydropyrido[2,3-f][1,4]oxazepin-5-one; and

(3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-8-(trifluoromethyl)-2,3-dihydro-1H-pyrido[2,3-f][1,4]diazepin-5-one,

or a pharmacologically acceptable salt thereof.

26. (3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3-methyl-8-(trifluoromethyl)-2,3-dihydropyrido[3,4-f][1,4]oxazepin-5-one, or a pharmacologically acceptable salt thereof.


27. (6R)-2-cyclopropyl-5-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-7,8-dihydro-6H-pyrazolo[1,5-a][1,4]diazepin-4-one, or a pharmacologically acceptable salt thereof.

28. (3R)-4-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-3,8-dimethyl-2,3-dihydropyrido[3,4-f][1,4]oxazepin-5-one, or a pharmacologically acceptable salt

thereof.

29. (6R)-2-cyclopropyl-7-[2-(2-fluorophenyl)sulfonyl-2-azaspiro[3.3]heptan-6-yl]-6-methyl-5,6-dihydrothiazolo[5,4-f][1,4]oxazepin-8-one, or a pharmacologically acceptable salt thereof.

30. The compound or the pharmacologically acceptable salt thereof according to claim 1, wherein the compound of Formula [I] is a compound represented by the following Formula [III]:



[III]

wherein,

a ring A represents an aryl group which may be substituted, a heteroaryl group which may be substituted, or an aliphatic heterocyclyl group which may be substituted, and

a ring D represents an aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring.

31. The pharmacologically acceptable salt thereof according to claim 30, wherein in the group represented by Formula [III],

each of substituents of the aryl group which may be substituted, the heteroaryl group which may be substituted, or the aliphatic heterocyclyl group which may be substituted represented by the ring A is one to three groups independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, an alkoxyalkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, an alkoxycarbonyl group, an amino group which may be substituted with one to two alkyl groups, an alkylthio group, a sulfonyl group which may be substituted with an alkyl group, an aminocarbonyl group which may be substituted with one to two alkyl groups, a nitro group, and aryl group,

an aryl moiety of the aryl group which may be substituted represented by the ring A is a 6- to 10-membered monocyclic or bicyclic aryl,

a heteroaryl moiety of the heteroaryl group which may be substituted

represented by the ring A is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted represented by the ring A is a 5- to 10-membered monocyclic or bicyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

each of substituents of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring D is one to eight groups independently selected from the group consisting of an oxo group; a an alkyl group which may be substituted; a cycloalkyl group; an aryl group; a heteroaryl group; an aliphatic heterocyclyl group; an alkoxy group; a cycloalkoxy group; an alkylthio group; an amino group; an alkoxycarbonyl group; an alkanoyl group; an alkylsulfonyl group; a halogen atom; a hydroxyl group; and cyano group, and

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring D is a 5- to 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

32. The compound or the pharmacologically acceptable salt thereof according to claim 30, wherein in the group represented by Formula [III],

the ring A is a phenyl group which may be substituted or a monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the monocyclic heteroaryl group which may be substituted represented by the ring A is one to two groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, and a nitro group,

a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted represented by the ring A is a 5- or 6-membered monocyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

each of substituents of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring D is one to eight groups independently selected from the group consisting of an oxo group; a an alkyl group which may be substituted; a cycloalkyl group; an aryl group; a heteroaryl group; an aliphatic heterocyclyl group; an alkoxy group; a cycloalkoxy group; an

alkylthio group; an amino group; an alkoxycarbonyl group; an alkanoyl group; an alkylsulfonyl group; a halogen atom; a hydroxyl group; and cyano group,

in each of the substituents of the groups represented by the ring D, each of substituents of the alkyl group which may be substituted in the selected group is one to five groups independently selected from the group consisting of a cycloalkyl group which may be substituted with an oxo group, a haloalkyl group, or a halogen atom; an aryl group which may be substituted with an alkyl group or a halogen atom; a heteroaryl group which may be substituted with an alkyl group; an aliphatic heterocyclyl group which may be substituted with an oxo group; a halogen atom; a hydroxyl group; a cyano group; an alkoxy group; a cycloalkoxy group; a haloalkoxy group; an amino group; an alkylamino group; a dialkylamino group; a cycloalkylamino group; and alkylthio group, and

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring D is a 5- to 7-membered monocyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur.

33. The compound or the pharmacologically acceptable salt thereof according to claim 30, wherein in the group represented by Formula [III],

the ring A is a phenyl group which may be substituted or a monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the monocyclic heteroaryl group which may be substituted represented by the ring A is one to two groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, and a nitro group,


a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted represented by the ring A is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, or triazinyl,

each of substituents of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring D is one to eight groups independently selected from the group consisting of an oxo group; a an alkyl group which may be substituted; a cycloalkyl group; an aryl group; a heteroaryl group; an aliphatic heterocyclyl group; an alkoxy group; a cycloalkoxy group; an alkylthio group; an amino group; an alkoxycarbonyl group; an alkanoyl group; an alkylsulfonyl group; a halogen atom; a hydroxyl group; and cyano group,

in each of the substituents of the groups represented by the ring D, each of substituents of the alkyl group which may be substituted in the selected group is one to five groups independently selected from the group consisting of a cycloalkyl group which may be substituted with an oxo group, a haloalkyl group, or a halogen atom; an aryl group which may be substituted with an alkyl group or a halogen atom; a heteroaryl group which may be substituted with an alkyl group; a heterocyclyl group which may be substituted with an oxo group; a halogen atom; a hydroxyl group; a cyano group; an alkoxy group; a cycloalkoxy group; a haloalkoxy group; an amino group; an alkylamino group; a dialkylamino group; a cycloalkylamino group; and alkylthio group, and

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring D is azolidinyl, diazolidinyl, azinanyl, oxazinanyl, diazinanyl, thiazinanyl, azepanil, oxazepanil, diazepanil, or thiazepanil.

34. The compound or the pharmacologically acceptable salt thereof according to claim 1, wherein the compound of Formula [I] is a compound represented by the following Formula [IV]:



[IV]

wherein,

a ring A represents an aryl group which may be substituted, a heteroaryl group which may be substituted, or an aliphatic heterocyclyl group which may be substituted,

R^1 represents an alkyl group which may be substituted, a cycloalkyl group which may be substituted, an alkenyl group which may be substituted, a cycloalkenyl group which may be substituted, an alkynyl group which may be substituted, an aryl group which may be substituted, a heteroaryl group which may be substituted, an aliphatic heterocyclyl group which may be substituted, an amino group which may be substituted, an alkoxy group which may be substituted, or an alkylthio group which may be substituted, and

a ring E represents an aryl group which may be substituted, a heteroaryl group which may be substituted, or an aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring.

35. The compound or the pharmacologically acceptable salt thereof according to claim 34, wherein in the group represented by Formula [IV],

each of substituents of the aryl group which may be substituted, the heteroaryl group which may be substituted, or the aliphatic heterocyclyl group which may be substituted represented by the ring A is one to three groups independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, an alkoxyalkyl group, a haloalkyl group, an alkoxy group, a haloalkoxy group, an alkanoyl group, an alkoxycarbonyl group, an amino group which may be substituted with one to two alkyl groups, an alkylthio group, a sulfonyl group which may be substituted with an alkyl group, an aminocarbonyl group which may be substituted with one to two alkyl groups, a nitro group, and aryl group,

an aryl moiety of the aryl group which may be substituted represented by the ring A is a 6- to 10-membered monocyclic or bicyclic aryl,

a heteroaryl moiety of the heteroaryl group which may be substituted represented by the ring A is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted represented by the ring A is a 5- to 10-membered monocyclic or bicyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

R^1 is an alkyl group which may be substituted, a cycloalkyl group which may be substituted, an alkenyl group which may be substituted, a cycloalkenyl group which may be substituted, or an alkynyl group which may be substituted,

each of substituents of the alkyl group which may be substituted, the alkenyl group which may be substituted, and the alkynyl group which may be substituted in the group represented by R^1 is a cycloalkyl group or a cycloalkenyl group,

each of substituents of the cycloalkyl group which may be substituted, and the cycloalkenyl group which may be substituted is an alkyl group, an alkenyl group or an alkynyl group,

an aryl moiety of the aryl group which may be substituted represented by the ring E is a 6- to 10-membered monocyclic or bicyclic aryl,

a heteroaryl moiety of the heteroaryl group which may be substituted represented by the ring E is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen,

nitrogen, and sulfur,

an aliphatic heterocyclic moiety of the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring E is a 5- to 10-membered monocyclic or bicyclic aliphatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, and

each of substituents of the aryl group which may be substituted, the heteroaryl group which may be substituted, or the aliphatic heterocyclyl group which may be substituted and may have a double bond in a part of a ring represented by the ring E is one to three groups independently selected from the group consisting of an alkyl group; a cycloalkyl group; an aryl group; a heteroaryl group; a halogen atom; a haloalkyl group; a hydroxyl group; a cyano group; an alkoxy group; a cycloalkoxy group; an aryloxy group; a haloalkoxy group; an amino group; an alkylamino group; a dialkylamino group; a cycloalkylamino group; and an alkylthio group.

36. The compound or the pharmacologically acceptable salt thereof according to claim 34, wherein in the group represented by Formula [IV],

the ring A is a phenyl group which may be substituted or a monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the monocyclic heteroaryl group which may be substituted represented by the ring A is one to two groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, a nitro group, and aryl group,

a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted represented by the ring A is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur,

R^1 is an alkyl group which may be substituted, a cycloalkyl group which may be substituted, an alkenyl group which may be substituted, a cycloalkenyl group which may be substituted, or an alkynyl group which may be substituted,

each of substituents of the alkyl group which may be substituted, the alkenyl group which may be substituted, and the alkynyl group which may be substituted in the group represented by R^1 is a cycloalkyl group or a cycloalkenyl group,

each of substituents of the cycloalkyl group which may be substituted, and the cycloalkenyl group which may be substituted in the group represented by R^1 is an alkyl group, an alkenyl group or an alkynyl group,

the ring E is an aryl group which may be substituted, or a heteroaryl group which may be substituted,

an aryl moiety of the aryl group which may be substituted represented by the ring E is a 6- to 10-membered monocyclic or bicyclic aryl,

a heteroaryl moiety of the heteroaryl group which may be substituted represented by the ring E is a 5- to 10-membered monocyclic or bicyclic heteroaryl having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, and

each of substituents of the aryl group which may be substituted, and the heteroaryl group which may be substituted represented by the ring E is one to three groups independently selected from the group consisting of an alkyl group; a cycloalkyl group; an aryl group; a heteroaryl group; a halogen atom; a haloalkyl group; a hydroxyl group; a cyano group; an alkoxy group; a cycloalkoxy group; an aryloxy group; a haloalkoxy group; an amino group; an alkylamino group; a dialkylamino group; a cycloalkylamino group; and an alkylthio group.

37. The compound or the pharmacologically acceptable salt thereof according to claim 34, wherein in the group represented by Formula [IV],

the ring A is a phenyl group which may be substituted or a monocyclic heteroaryl group which may be substituted,

each of substituents of the phenyl group which may be substituted or the monocyclic heteroaryl group which may be substituted represented by the ring A is one to two groups independently selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an alkoxy group, a nitro group, and an aryl group,

a heteroaryl moiety of the monocyclic heteroaryl group which may be substituted represented by the ring A is pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, or triazinyl,

R^1 is an alkyl group,

the ring E is an aryl group which may be substituted, or a heteroaryl group which may be substituted,

an aryl moiety of the aryl group which may be substituted represented by the ring E is phenyl or naphthyl,

a heteroaryl moiety of the heteroaryl group which may be substituted represented by the ring E is pyridyl, azaindolyl, imidazopyridyl or benzoimidazolyl, and

each of substituents of the aryl group which may be substituted, and the

heteroaryl group which may be substituted represented by the ring E is a group independently selected from the group consisting of an alkyl group; a cycloalkyl group; an aryl group; a heteroaryl group; a halogen atom; a haloalkyl group; a hydroxyl group; a cyano group; an alkoxy group; a cycloalkoxy group; an aryloxy group; a haloalkoxy group; an amino group; an alkylamino group; a dialkylamino group; a cycloalkylamino group; and an alkylthio group.

38. A pharmaceutical composition comprising the compound or the pharmacologically acceptable salt thereof according to any one of claims 1 to 37 as an active ingredient.

39. The pharmaceutical composition according to claim 38, for use in preventing or treating various diseases and/or symptoms associated therewith that are ameliorated by increasing a central TRH concentration, or for use in improving prognosis of these diseases and/or symptoms associated therewith.

40. The pharmaceutical composition according to claim 39, for use in preventing or treating spinocerebellar degeneration, chronic pain, a sleep disorder, or other psychoneurotic diseases and/or symptoms associated therewith.

41. The pharmaceutical composition according to claim 40, wherein the chronic pain is neuropathic pain or nociceptive pain.

42. The pharmaceutical composition according to claim 41, wherein the neuropathic pain is pain associated with diabetic neuropathy, postherpetic neuralgia, pain associated with peripheral neuropathy due to chemotherapy, trigeminal neuralgia, complex regional pain syndrome, post-stroke pain, spinal cord injury pain, neuralgia, or pain associated with nerve damage.

43. The pharmaceutical composition according to claim 41, wherein the nociceptive pain is pain associated with rheumatoid arthritis, pain associated with osteoarthritis deformans, postoperative pain, or myofascial pain.

44. The pharmaceutical composition according to claim 40, wherein the sleep disorder is hypersomnia, a circadian rhythm disorder, sleep-disordered breathing, or other sleep disorders.

45. The pharmaceutical composition according to claim 44, wherein the hypersomnia is narcolepsy, idiopathic hypersomnia, or repetitive hypersomnia.

46. The pharmaceutical composition according to claim 44, wherein the circadian rhythm disorder is a sleep disorder due to shift work, delayed sleep phase syndrome, advanced sleep phase syndrome, non-24-hour sleep-wake syndrome, or an irregular sleep-wake pattern.

47. The pharmaceutical composition according to claim 44, wherein the sleep-disordered breathing is sleep apnea syndrome.

48. The pharmaceutical composition according to claim 44, wherein the other sleep disorders are jet lag syndrome, desynchronosis syndrome, restless legs syndrome, a periodic limb movement disorder, hypersomnia associated with insomnia associated with a neurological disorder or a mental disorder, or a rapid eye movement (REM) sleep behavior disorder.

49. The pharmaceutical composition according to claim 40, wherein the other psychoneurotic diseases and/or the symptoms associated therewith are spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, chronic fatigue syndrome, vascular dementia, a bipolar disorder, depression, a spinal cord injury, cerebral infarction, head trauma, a pervasive consciousness disorder, a language disorder, fatigability, dysfunction due to nerve damage, or dysfunction due to surgery.

50. Use of compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 37, or a pharmaceutical composition according to claim 38, in the manufacture of a medicament for preventing or treating various diseases and/or symptoms associated therewith that are ameliorated by increasing a central TRH concentration, or for improving prognosis of these diseases and/or symptoms associated therewith in a patient.

51. The use according to claim 50, wherein the various diseases and/or the symptoms associated therewith that are ameliorated by increasing a central TRH concentration are spinocerebellar degeneration, chronic pain, a sleep disorder, or other

psychoneurotic diseases and/or symptoms associated therewith.

52. The use according to claim 51, wherein the chronic pain is neuropathic pain or nociceptive pain.

53. The use according to claim 52, wherein the neuropathic pain is pain associated with diabetic neuropathy, postherpetic neuralgia, pain associated with peripheral neuropathy due to chemotherapy, trigeminal neuralgia, complex regional pain syndrome, post-stroke pain, spinal cord injury pain, neuralgia, or pain associated with nerve damage.

54. The use according to claim 52, wherein the nociceptive pain is pain associated with rheumatoid arthritis, pain associated with osteoarthritis deformans, postoperative pain, or myofascial pain.

55. The use according to claim 51, wherein the sleep disorder is hypersomnia, a circadian rhythm disorder, sleep-disordered breathing, or other sleep disorders.

56. The use according to claim 55, wherein the hypersomnia is narcolepsy, idiopathic hypersomnia, or repetitive hypersomnia.

57. The use according to claim 55, wherein the circadian rhythm disorder is a sleep disorder due to shift work, delayed sleep phase syndrome, advanced sleep phase syndrome, non-24-hour sleep-wake syndrome, or an irregular sleep-wake pattern.

58. The use according to claim 55, wherein the sleep-disordered breathing is sleep apnea syndrome.

59. The use according to claim 55, wherein the other sleep disorders are jet lag syndrome, desynchronosis syndrome, restless legs syndrome, a periodic limb movement disorder, hypersomnia associated with insomnia associated with a neurological disorder or a mental disorder, or a rapid eye movement (REM) sleep behavior disorder.

60. The use according to claim 51, wherein the other psychoneurotic diseases and/or the symptoms associated therewith are spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, chronic fatigue syndrome,

vascular dementia, a bipolar disorder, depression, a spinal cord injury, cerebral infarction, head trauma, a pervasive consciousness disorder, a language disorder, fatigability, dysfunction due to nerve damage, or dysfunction due to surgery.